Antibodies that target the inflammatory cytokine IL-23 are the most promising new therapies for IBD likely to emerge in the next five years, according to a presentation at UEG Week 2020 Virtual meeting. There are now four anti-IL23 therapies in phase 3 trials and they appear to be highly effective in both Crohns disease and ...
IL-23 mabs will transform IBD treatment: UEG 2020
By Michael Woodhead
15 Oct 2020